OUTCOME AND TOXICITY OF TOTAL NEOADJUVANT THERAPY IN RECTAL CANCER

Conditions

C20

Wurschi GW, Hinz A, Schneider M, Becker JN, Frerker B, Vorbach SM, Ehret F, Diefenhardt M, Schunn F, von Gruben ME, Büttner M, Hoffmann E, Rühle A, Beier J, Ferdinandus S, Trommer M, Sahin EC, Hlouschek J, Aninditha K, von Ohlen DS, Kaufmann J, Depardon A, Ha HM, Kessler C, Cieslak A, Trommer S, Fabian A, Rißner F, Römer M, Pietschmann K.

2026-02-18

10.1002/ijc.70396

Short-course radiotherapy versus long-course chemoradiotherapy in total neoadjuvant therapy of rectal cancer - A multicenter analysis of early outcomes and toxicity.

Wurschi G, Kesselmeier M, Schneider M, Becker JN, Frerker B, Vorbach SM, Ehret F, Diefenhardt M, Schunn F, von Gruben ME, Büttner M, Hoffmann E, Rühle A, Beier J, Ferdinandus S, Trommer M, Sahin EC, Hlouschek J, Aninditha K, von Ohlen DS, Kaufmann J, Depardon A, Ha HM, Trommer S, Kessler C, Cieslak A, Fabian A, Rißner F, Römer M, Mäurer M, Pietschmann K.

2025-10-10

10.1016/j.radonc.2025.111194

Short-course radiotherapy versus long-course chemoradiotherapy in total neoadjuvant therapy of rectal cancer : a multicenter analysis of early outcomes and toxicity

Wurschi, Georg, Trommer, Simon Manfred, [und viele weitere]

Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt)2025-01-01

10.25673/121599

Interventions

Group 1: A retrospective cohort of patients with rectal cancer who underwent (chemo)radiation followed by consolidating chemotherapy (so-called "total neoadjuvant therapy") between 2010 and January 20

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with locally advanced rectal cancer (LARC), UICC stage II/III who underwent total neoadjuvant therapy (TNT) adequately measured tumor response (histologically and / or radiologically plus endoscopically) available follow-up data (min. 6 months)

Exclusion criteria

Exclusion criteria: Enrollment in other ongoing clinical trials

Design outcomes

Primary

Measure	Time frame
complete remission rate	—

Secondary

Measure	Time frame
treatment schedule (i.e. fractionation of radiation, duration of radiation and chemotherapy respectively, chemotherapy dosing, cumulative chemotherapy dose) toxicity during and after therapy quality / results of surgery survival rates (overall, disease-free, colostomy-free), relapse rate quality of life	—

Countries

Germany

Contacts

Public ContactGeorg Wurschi

Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Jena

georg.wurschi@med.uni-jena.de0049 3641 9 32 84 01

Outcome results

None listed